Roche hemophilia drug lowers costs despite high price: ICER

(Reuters) – A costly new Roche Holding AG drug to treat the bleeding disorder hemophilia A could significantly reduce healthcare expenses for certain patients, a draft report from an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

https://www.reuters.com/article/us-roche-hemophilia-icer/roche-hemophilia-drug-lowers-costs-despite-high-price-icer-idUSKBN1FG00O

France’s Sanofi buys US hemophilia specialist Bioverativ

France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases. The deal announced Monday is the latest such move in a pharmaceutical industry that’s seeing increasing interest in rare diseases. http://www.topix.com/business/pharmaceuticals/2018/01/frances-sanofi-buys-us-hemophilia-specialist-bioverativ?fromrss=1

Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars

Sandoz, a Novartis division and the global leader in biosimilars, today announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide. http://www.worldpharmanews.com/novartis/4264-sandoz-announces-exclusive-global-collaboration-with-biocon-on-next-generation-biosimilars

Payers point to Spark’s gene therapy as a model for innovative pricing plans

When Spark Therapeutics announced last week an $850,000 price for its gene therapy Luxturna, some critics held it up as the latest example of an expensive new treatment that could break the bank for the healthcare system. But at the J.P. Morgan Healthcare conference this week, it was clear that sentiment is rapidly changing. https://www.fiercepharma.com/financials/payers-point-to-spark-s-gene-therapy-as-a-model-for-innovative-pricing-plans

Roche, GE Partnership to Develop Integrated Digital Diagnostics Platform to Improve Oncology

NewsRoche announced that it has entered into a strategic, long-term partnership with GE Healthcare in order to jointly develop and co-market digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.Contributed Author: RocheTopics: Disease Research https://www.dddmag.com/news/2018/01/roche-ge-partnership-develop-integrated-digital-diagnostics-platform-improve-oncology